{"nctId":"NCT00765674","briefTitle":"Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension","startDateStruct":{"date":"2008-09"},"conditions":["Hypertension"],"count":1191,"armGroups":[{"label":"Aliskiren / amlodipine","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren","Drug: Amlodipine","Drug: Placebo"]},{"label":"Aliskiren / hydrochlorothiazide","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren","Drug: Hydrochlorothiazide (HCTZ)","Drug: Placebo"]},{"label":"Amlodipine / hydrochlorothiazide","type":"EXPERIMENTAL","interventionNames":["Drug: Amlodipine","Drug: Hydrochlorothiazide (HCTZ)","Drug: Placebo"]},{"label":"Aliskiren / amlodipine / hydrochlorothiazide","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren","Drug: Amlodipine","Drug: Hydrochlorothiazide (HCTZ)","Drug: Placebo"]}],"interventions":[{"name":"Aliskiren","otherNames":[]},{"name":"Amlodipine","otherNames":[]},{"name":"Hydrochlorothiazide (HCTZ)","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female\n* 18 years of age or older\n* msDBP and msSBP requirements:\n\n  * 3A:\n\n    * Diagnosis of moderate to severe hypertension (msSBP ≥ 160 mmHg and \\< 200 mmHg, and/or msDBP ≥ 100 mmHg and \\< 120 mmHg) at Visits 4, 5 or 6 (Qualifying BP visit)\n    * In addition, at the visit immediately prior to the above qualifying visit, patients were also to have msSBP ≥ 145 mmHg and \\< 200 mmHg and msDBP ≥ 95 mmHg and \\< 120 mmHg) at Visits 3, 5 or 5.\n    * Patients had to meet the above two sets of requirements at subsequent adjacent visits, i.e. either Visits 3 and 4, Visits 4 and 5, or Visits 5 and 6.\n  * OR\n  * 3B:\n\n    * msSBP ≥ 180 mmHg and \\< 200 mmHg with msDBP ≥ 95 mmHg and \\< 120 mmHg, or msDBP ≥ 110 mmHg and \\< 120 mmHg with msSBP ≥ 150 mmHg and \\< 200 mmHg after at least one week of treatment with placebo (Visit 3 and on).\n\nExclusion Criteria:\n\n* Continued use of anti-hypertensive medicines or use of 4 or more hypertensive medicines at study start\n* Patients with an msSBP ≥ 200 mmHg or msDBP ≥ 120 mmHg at any time during the placebo run-in period were to be discontinued from the study.\n* Extremely elevated (defined) blood pressure at any point during the study\n* Pregnant or lactating women\n* Pre-menopausal women not taking accepted form of birth control\n* History or evidence of secondary form of hypertension\n* History of cardiovascular conditions\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)","description":"Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.37","spread":"0.90"},{"groupId":"OG001","value":"-27.99","spread":"0.88"},{"groupId":"OG002","value":"-30.77","spread":"0.88"},{"groupId":"OG003","value":"-37.92","spread":"0.86"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)","description":"Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.03","spread":"0.57"},{"groupId":"OG001","value":"-14.32","spread":"0.55"},{"groupId":"OG002","value":"-17.03","spread":"0.55"},{"groupId":"OG003","value":"-20.63","spread":"0.54"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving Blood Pressure Control at the End of the Study (Week 8)","description":"Blood pressure control was defined as a msSBP/msDBP \\< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"33.1","spread":null},{"groupId":"OG002","value":"39.0","spread":null},{"groupId":"OG003","value":"62.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Mean 24-hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study (Week 8)","description":"Twenty-four hour ambulatory blood pressure monitoring (ABPM) was performed in a subset of patients twice during the study, once at baseline and again at Week 8. The ABPM device was placed on the non-dominant arm between 7:00 and 10:00 am and verification readings obtained. If they were successful, the investigator initiated the 24 hour reading and instructed the patient regarding ABPM procedures. On the next day, the ABPM device was removed if it had been worn for a minimum of 24 hours. The ABPM data were downloaded and evaluated on site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.30","spread":"0.52"},{"groupId":"OG001","value":"-16.27","spread":"0.51"},{"groupId":"OG002","value":"-18.67","spread":"0.53"},{"groupId":"OG003","value":"-25.29","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.29","spread":"0.36"},{"groupId":"OG001","value":"-9.57","spread":"0.35"},{"groupId":"OG002","value":"-11.20","spread":"0.37"},{"groupId":"OG003","value":"-15.90","spread":"0.35"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":287},"commonTop":["Oedema peripheral","Headache"]}}}